VCYT Strangle Strategy

VCYT (Veracyte, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT (Veracyte, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $3.05B, a trailing P/E of 34.57, a beta of 1.89 versus the broader market, a 52-week range of 22.61-50.71, average daily share volume of 943K, a public-listing history dating back to 2013, approximately 824 full-time employees. These structural characteristics shape how VCYT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.89 indicates VCYT has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on VCYT?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current VCYT snapshot

As of May 15, 2026, spot at $38.55, ATM IV 68.50%, IV rank 33.06%, expected move 19.64%. The strangle on VCYT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on VCYT specifically: VCYT IV at 68.50% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 19.64% (roughly $7.57 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated VCYT expiries trade a higher absolute premium for lower per-day decay. Position sizing on VCYT should anchor to the underlying notional of $38.55 per share and to the trader's directional view on VCYT stock.

VCYT strangle setup

The VCYT strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With VCYT near $38.55, the first option leg uses a $40.48 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed VCYT chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 VCYT shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$40.48	N/A
Buy 1	Put	$36.62	N/A

VCYT strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

VCYT strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on VCYT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on VCYT

Strangles on VCYT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the VCYT chain.

VCYT thesis for this strangle

The market-implied 1-standard-deviation range for VCYT extends from approximately $30.98 on the downside to $46.12 on the upside. A VCYT long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current VCYT IV rank near 33.06% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on VCYT should anchor more to the directional view and the expected-move geometry. As a Healthcare name, VCYT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to VCYT-specific events.

VCYT strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. VCYT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move VCYT alongside the broader basket even when VCYT-specific fundamentals are unchanged. Always rebuild the position from current VCYT chain quotes before placing a trade.

Frequently asked questions

What is a strangle on VCYT?: A strangle on VCYT is the strangle strategy applied to VCYT (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With VCYT stock trading near $38.55, the strikes shown on this page are snapped to the nearest listed VCYT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are VCYT strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the VCYT strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 68.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a VCYT strangle?: The breakeven for the VCYT strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current VCYT market-implied 1-standard-deviation expected move is approximately 19.64%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on VCYT?: Strangles on VCYT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the VCYT chain.
How does current VCYT implied volatility affect this strangle?: VCYT ATM IV is at 68.50% with IV rank near 33.06%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.